Cargando…

Association of exercise participation levels with cardiometabolic health and quality of life in individuals with hepatitis C

OBJECTIVE: Hepatitis C virus (HCV) infection is associated with an increased risk of cardiovascular disease (CVD) and reduced health-related quality of life (HRQoL). Although physical activity (PA)/exercise has been shown to reduce CVD risk and improve HRQoL in patients with liver disease, there is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hallsworth, Kate, Gosrani, Shion, Hogg, Sarah, Patel, Preya, Wetten, Aaron, Welton, Rachael, McPherson, Stuart, Campbell, Matthew D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993332/ https://www.ncbi.nlm.nih.gov/pubmed/33762303 http://dx.doi.org/10.1136/bmjgast-2020-000591

Ejemplares similares

Increased cardiovascular risk and reduced quality of life are highly prevalent among individuals with hepatitis C
por: McPherson, Stuart, et al.
Publicado: (2020)

Stratification Of LIver Disease (SOLID): protocol for a prospective observational cohort study to determine the optimum biomarker strategies for the detection of advanced liver disease at the primary–secondary care interface
por: McPherson, Stuart, et al.
Publicado: (2023)

Factors associated with engagement and adherence to a low-energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease
por: Scragg, Jadine, et al.
Publicado: (2021)

Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss
por: Hallsworth, Kate, et al.
Publicado: (2011)

Uncovering undiagnosed liver disease: prevalence and opportunity for intervention in a population attending colonoscopy
por: Koo, Sara, et al.
Publicado: (2021)

COVID-19 and liver cancer: lost patients and larger tumours
por: Geh, Daniel, et al.
Publicado: (2022)

Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease
por: Hardy, Timothy, et al.
Publicado: (2017)

Nutrigenetics-based intervention approach for adults with non-alcoholic fatty liver disease (NAFLD): study protocol for a randomised controlled feasibility trial
por: Haigh, Laura, et al.
Publicado: (2021)

Effect of physical exercise on sarcopaenia in patients with overt hepatic encephalopathy: a study protocol for a randomised controlled trial
por: Yoh, Kazunori, et al.
Publicado: (2017)

Is there scope to improve the selection of patients with alcohol-related liver disease for referral to secondary care? A retrospective analysis of primary care referrals to a UK liver centre, incorporating simple blood tests
por: Rhodes, Freya Alison, et al.
Publicado: (2021)

Home-based exercise in patients with refractory fatigue associated with primary biliary cholangitis: a protocol for the EXerCise Intervention in cholesTatic LivEr Disease (EXCITED) feasibility trial
por: Freer, Alice, et al.
Publicado: (2021)

Barriers to implementation of stratified care in primary biliary cholangitis: a scoping exercise
por: Corrigan, Margaret, et al.
Publicado: (2019)

MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure
por: Triantafyllou, Evangelos, et al.
Publicado: (2018)

Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection
por: Fitzmaurice, Karen, et al.
Publicado: (2011)

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis
por: Mózes, Ferenc Emil, et al.
Publicado: (2022)

Viral hepatitis in 2021: The challenges remaining and how we should tackle them
por: Dunn, Rebecca, et al.
Publicado: (2022)

Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China
por: Zhang, H W, et al.
Publicado: (2008)

Identification of circulating microRNAs as potential biomarkers for hepatic necroinflammation in patients with autoimmune hepatitis
por: Saeki, Chisato, et al.
Publicado: (2022)

Primary hepatic large B-cell lymphoma following direct-acting antiviral treatment for hepatitis C
por: Zaimi, Yosra, et al.
Publicado: (2021)

An educational tool for the prophylaxis of hepatic encephalopathy
por: Garrido, Maria, et al.
Publicado: (2017)

Hepatitis C elimination in the Netherlands (CELINE): study protocol for nationwide retrieval of lost to follow-up patients with chronic hepatitis C
por: Isfordink, Cas J, et al.
Publicado: (2020)

Loss of hepatic Mboat7 leads to liver fibrosis
por: Thangapandi, Veera Raghavan, et al.
Publicado: (2021)

Managing hepatic complications of pregnancy: practical strategies for clinicians
por: Morrison, Maura Alice, et al.
Publicado: (2022)

In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome
por: Todt, Daniel, et al.
Publicado: (2016)

Low yield of head CT in cirrhotic patients presenting with hepatic encephalopathy
por: Hanna, Angy, et al.
Publicado: (2021)

Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues
por: Fan, Rong, et al.
Publicado: (2016)

Hepatic decompensation in the absence of obvious precipitants: the potential role of cytomegalovirus infection/reactivation
por: Rosi, Silvia, et al.
Publicado: (2015)

miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression
por: Hanin, Geula, et al.
Publicado: (2018)

Effect of season and sunlight on viral kinetics during hepatitis C virus therapy
por: Hernández-Alvarez, Noemi, et al.
Publicado: (2017)

Effect of COVID-19 on presentations of decompensated liver disease in Scotland
por: Manship, Thomas, et al.
Publicado: (2022)

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
por: Colombo, M, et al.
Publicado: (2014)

Comparable efficacy with entecavir monotherapy and tenofovir–entecavir combination in chronic hepatitis B patients
por: Baqai, Sumbella, et al.
Publicado: (2015)

Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study
por: Volpato, Sofia, et al.
Publicado: (2017)

Autoantibodies in chronic hepatitis C virus infection: impact on clinical outcomes and extrahepatic manifestations
por: Gilman, Andrew J, et al.
Publicado: (2018)

Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus
por: Carpentier, Arnaud, et al.
Publicado: (2020)

Unexpected clinical outcomes following the implementation of a standardised order set for hepatic encephalopathy
por: KC, Mandip, et al.
Publicado: (2021)

Value and risk of percutaneous liver biopsy in patients with cirrhosis and clinical suspicion of autoimmune hepatitis
por: Sripongpun, Pimsiri, et al.
Publicado: (2021)

Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus
por: Llibre, Alba, et al.
Publicado: (2018)

Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma
por: Péneau, Camille, et al.
Publicado: (2022)

Polyethylene glycol versus lactulose in the treatment of hepatic encephalopathy: a systematic review and meta-analysis
por: Hoilat, Gilles Jadd, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rob8b278eaa458dcevf874vimn